Unaudited September 2026 results show revenue and profit growth

Compliance View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.8%Reaction day

₹1388.80

prior close

₹1362.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 170sector+0.6%-4.4% vs sector

On the reaction day the stock moved 4.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-1.2

15m

-0.7

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.8pendingpending+0.6-4.4

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies published unaudited consolidated results for the quarter and half year ended 30 September 2026. Quarter revenue was Rs 218.76 crore versus Rs 192.75 crore; half-year revenue was Rs 397.62 crore versus Rs 329.93 crore. Profit after tax was Rs 25.65 crore versus Rs 20.13 crore for the quarter and Rs 48.62 crore versus Rs 29.73 crore for the half year. Earnings per share were Rs 19.19 and Rs 36.37, respectively.

Likely market impact

Higher revenue and profit support a positive view of earnings, though results are unaudited and stock reaction will depend on market expectations.